I think OCRX has a fair—but not great—chance of persuading the FDA to endorse advancing OCR-002 to phase-3, using the kind of trial design proposed on today's CC.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.